Capital Research & Management Co has recently announced that it has increased stake in Takeda Pharmaceutical Co ADR (NYSE:TAK) by 0.05%. After grabbing 13.79 million shares, the institutional investor is now in possession of 6518.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.44% having worth around $195.19 million. Moreover, Parametric Portfolio Associates L increased its share by 0.14 million to have a control over 4.41 million shares. And Millennium Management LLC raised its holdings to 0.68 million shares by acquiring 3.76 million shares or 0.12% of the stake.
Takeda Pharmaceutical Co ADR (TAK) concluded trading on 12/21/23 at a closing price of $13.97, with 2.03 million shares of worth about $28.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.25% during that period and on Thursday the price saw a gain of about 2.05%. Currently the company’s common shares owned by public are about 3.14B shares, out of which, 3.14B shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 17 analysts are covering the TAK stock and their offered price forecasts bring an average price target of $4683.33. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $5800.00 and could fall to a lowest price of $4100.00. The stock’s current price level is 12.03% above of average price target set by the analysts, while a rise to estimated low would result in gain of 99.66% for the stock. However, touching the estimated high of $5800.00 would mean a gain of 99.76% for the stock.
American Mutual Fund, VanEck Pharmaceutical ETF, and Pacer Fds. Tr. – Global Cash Cows are the top 3 mutual funds which are holding stakes in Takeda Pharmaceutical Co ADR American Mutual Fund is currently holding 13.65 million shares of worth totaling $193.19 million. The company recently came selling 28415.0 shares which brought its stake up to 0.43% of the company’s outstanding shares. Pacer Fds. Tr. – Global Cash Cows, after buying 0.94 million shares, have now control over 0.03% of the stake in the company. It holds 0.0 shares of worth $13.37 million.
Takeda Pharmaceutical Co ADR (NYSE: TAK) started trading at $13.97, above $0.28 from concluding price of the previous day. However, the stock later moved at a day high price of 14.01, or with a gain of 2.05%. Stock saw a price change of -0.57% in past 5 days and over the past one month there was a price change of -0.36%. Year-to-date (YTD), TAK shares are showing a performance of -10.45% which decreased to -8.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.19 but also hit the highest price of $17.15 during that period. The average intraday trading volume for Takeda Pharmaceutical Co ADR shares is 1.94 million. The stock is currently trading -0.20% below its 20-day simple moving average (SMA20), while that difference is down -0.74% for SMA50 and it goes to -9.66% lower than SMA200.
Capital Research & Management Co acquired 13.79 million shares of Takeda Pharmaceutical Co ADR having value of about $195.19 million. Data submitted at the U.S SEC by Capital Research & Management Co revealed that the firm now holds 6518.0 shares in the company valued at close to $91056.46, or have control over 0.05% stake in the company. Takeda Pharmaceutical Co ADR (NYSE: TAK) currently have 3.14B outstanding shares and institutions hold larger chunk of about 2.56% of that. Holding of mutual funds in the company is about 0.57% while other institutional holders and individual stake holders have control over 1.96% and — of the stake respectively.
The stock has a current market capitalization of $43.84B and its 3Y-monthly beta is at 0.64. PE ratio of stock for trailing 12 months is 31.56, while it has posted earnings per share of $0.44 in the same period. Its PEG reads 1578.17 and has Quick Ratio of 0.55 while making debt-to-equity ratio of 0.66. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TAK, volatility over the week remained 1.34% while standing at 0.98% over the month.
Analysts are in expectations that Takeda Pharmaceutical Co ADR (TAK) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -56.53% while it is estimated to increase by 59.47% in next year. EPS is likely to grow at an annualized rate of 0.02% for next 5-years, compared to annual growth of -6.94% made by the stock over the past 5-years.
Analysts at 17 brokerage firms have issued recommendations for the Takeda Pharmaceutical Co ADR (TAK)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.06. Out of those 17 Wall Street analysts, 7 recommended a “Buy” rating, while 8 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on March 16, 2023 offering a Buy rating for the stock and assigned a target price of $20 to it.
